Oncopeptides (Q4 initial take): Higher Costs and Rights Issue - Redeye

Redeye comments on Oncopeptides Q4 report, whose topline has already been communicated. Costs were somewhat higher than we had forecast as was the cash burn. A rights issue of SEK200m was announced, which will fund Pepaxti and the preclinical pipeline.

Länk till analysen i sin helhet: https://www.redeye.se/research/1152575/oncopeptides-q4-initial-take-higher-costs-and-rights-issue?utm_source=finwire&utm_medium=RSS